Emergent receives FDA warning letter over quality control issues




  • In Business
  • 2022-08-12 22:22:05Z
  • By Reuters
 

(Reuters) - Emergent BioSolutions Inc said on Friday it had received a warning letter from the U.S. Food and Drug Administration, citing certain deficiencies at the contract drugmaker's manufacturing facility in Baltimore, Maryland.

The FDA pointed to deficiencies in cleaning and maintenance of equipment to prevent contamination of drug product and also recommended the company review its quality control process, Emergent said.

Earlier in August, Emergent had said the FDA had last inspected its facility at Camden in February and was waiting for the agency's feedback. The contract drugmaker said it was also conducting additional reviews with a third party in the meantime to ensure "delivery of medically necessary products".

Emergent has struggled with quality issues at another one of its Baltimore plants that had been making Johnson & Johnson's COVID-19 vaccine.

Manufacturing at Emergent's Bayview plant was briefly halted last year after a discovery that ingredients from AstraZeneca's COVID-19 vaccine, also being produced there at that time, contaminated a batch of J&J's vaccines.

J&J gave notice to terminate its vaccine manufacturing agreement with the contract manufacturer in June.

Shares of Emergent were down 2.3% at $29.80 in after-market trading.

(Reporting by Amruta Khandekar in Bengaluru; Editing by Krishna Chandra Eluri)

COMMENTS

More Related News

Pfizer-BioNTech asks FDA to authorize new omicron-targeting COVID booster for children 5 to 11
Pfizer-BioNTech asks FDA to authorize new omicron-targeting COVID booster for children 5 to 11

Pfizer-BioNTech submitted an application for the FDA to authorize its BA.4/BA.5 bivalent COVID-19 vaccine for kids 5 to 11 at a 10-microgram dose.

Pfizer seeks to expand omicron booster to 5- to 11-year-olds
Pfizer seeks to expand omicron booster to 5- to 11-year-olds

Pfizer asked U.S. regulators Monday to expand use of its updated COVID-19 booster shot to children ages 5 to 11. If the Food and Drug Administration agrees, they would start getting a kid-sized dose of the new omicron-targeted formula when it was time for their booster. FDA vaccine chief Dr. Peter Marks said last week he expected a decision on boosters for that age group soon.

Leave a Comment

Your email address will not be published. Required fields are marked with *

Cancel reply

Comments

Top News: Business